RBC
IONS icon

Romano Brothers & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Romano Brothers & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,148
Closed -$43.4K – 610
2022
Q4 		$43.4K Buy
+1,148
New +$48.3K 0.01% 494

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Romano Brothers & Co's IONS Position: Q1 2023 in Review

Romano Brothers & Co sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 1,148 shares — an estimated $43.4K sold.

Romano Brothers & Co first reported a position in IONS in Q4 2022 and held it in 1 quarter. The position peaked at $43.4K in Q4 2022. 313 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

  • Romano Brothers & Co reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 1,148 Ionis Pharmaceuticals shares in Q1 2023, an estimated $43.4K.
  • Romano Brothers & Co first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Ionis Pharmaceuticals position peaked at $43.4K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.